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Abstract
Background: The way we formulate a mathematical model of an infectious disease to capture symptomatic and
asymptomatic transmission can greatly influence the likely effectiveness of vaccination in the presence of vaccine effect for
preventing clinical illness. The present study aims to assess the impact of model building strategy on the epidemic
threshold under vaccination.
Methodology/Principal Findings: We consider two different types of mathematical models, one based on observable
variables including symptom onset and recovery from clinical illness (hereafter, the ‘‘observable model’’) and the other
based on unobservable information of infection event and infectiousness (the ‘‘unobservable model’’). By imposing a
number of modifying assumptions to the observable model, we let it mimic the unobservable model, identifying that the
two models are fully consistent only when the incubation period is identical to the latent period and when there is no pre-
symptomatic transmission. We also computed the reproduction numbers with and without vaccination, demonstrating that
the data generating process of vaccine-induced reduction in symptomatic illness is consistent with the observable model
only and examining how the effective reproduction number is differently calculated by two models.
Conclusions: To explicitly incorporate the vaccine effect in reducing the risk of symptomatic illness into the model, it is
fruitful to employ a model that directly accounts for disease progression. More modeling studies based on observable
epidemiological information are called for.
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Introduction
There are two intriguing characteristics in quantitatively
modeling infectious disease data. First, the risk of infection to an
individual is dependent on the risks of other individuals in the
same population unit. Second, the infection event is seldom
directly observable. Among these two, the dependence has been
addressed during the process of model building, e.g., a heteroge-
neous contact structure has been explicitly considered in various
types of models [1] and sometimes by examining the conditional
risk of infection at a confined setting (e.g. household). On the other
hand, it has been common to address the unobservable nature of
infection event by employing a convolution equation, i.e. the so-
called ‘‘backcalculation method’’, to infer the time of infection
based on the dataset of illness onset [2–5]. However, the
deconvolution procedure has been frequently dealt with as a
statistical technique that is independent of the transmission model
[6], and the process of model building tended to be separated from
the unobservable character of infection event.
Ignoring the unobservable nature during model formulation
would complicate the model fitting to empirical data. In many
instances, a temporal distribution of infected individuals (i.e. an
epidemic curve) is analyzed, and most frequently, the best
available dataset is the daily counts of cases. The data are usually
collected based on observable information only, e.g. counts of
cases according to the date of diagnosis of clinically apparent
illness. Only in the better case, epidemiologists are granted an
access to the daily frequency of illness onset. Nevertheless, the data
generating process of the empirical information is rather different
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from assumed transition mechanism within the so-called SIR
(susceptible-infectious-removed) model. The SIR model is consid-
ered as inconsistent with the data, because the transition from S to
I state is determined by the event of infection (which is
unobservable) and the other transition from I to R state is
determined by the loss of infectiousness (which is even more
difficult to observe) [7]. In light of a need to construct a model that
better adheres to the observable information, a previous study
proposed a novel modeling approach that classifies infected
individuals into asymptomatic and symptomatic ones while still
adopting a common multistate model structure [8]. In the case of
the unobservable SEIR (susceptible-exposed-infectious-removed)
model, the model handles unobservable information within the
multistate structure, classifying infected individuals into pre-
infectious (exposed) and infectious individuals [7,8] that are not
directly distinguishable from each other in empirical observation.
Although a previous study recognized the importance of
asymptomatic transmission in considering the feasibility of non-
pharmaceutical public health interventions (e.g. contact tracing
and case isolation) [9], the impact of correctly and precisely
capturing the natural course of ‘‘illness’’ on the effectiveness of
interventions (e.g. vaccination) has yet to be discussed. In the past,
the contribution of asymptomatic individuals to the transmission
dynamics tended to be modeled by employing the widely adopted
SEIR model while splitting infectious individuals (I-class) into
symptomatic and asymptomatic cases (e.g. [10]). The underlying
assumptions and any potential drawbacks for employing the SEIR
model on this matter have not been clarified, and thus, we would
like to examine if an epidemic threshold (which yields the critical
vaccination coverage) is greatly influenced by the abovementioned
difference in model building approaches.
Employing a mathematical modeling approach, the present
study aims to assess the impact of model building strategy on the
transmission dynamics of an infectious disease under vaccination
practice. In particular, we investigate differential values of
epidemic threshold between models that rest on observable and
unobservable information.
Materials and Methods
Two models
We consider two different types of mathematical models, one
based on observable variables including symptom onset and
recovery from clinical illness (hereafter referred to as the
‘‘observable model’’) and the other based on unobservable
information including infection event and infectiousness (the
‘‘unobservable model’’). Whereas the unobservable model in the
following is a variant of the SEIR model [10], the observable
model considers the transition of infected individuals based on
illness onset and the disappearance of symptoms that are directly
visible in the field data [8] (Figure 1A and 1B). The word
‘‘observable’’ is intended to reflect the presence of observable
symptoms (i.e. not including those observed or detected by
employing laboratory testing during the asymptomatic period).
Thus, the observable model might also be referred to the
‘‘symptom-based’’ model. Similarly, the unobservable model
may be referred to as the ‘‘contagiousness-dependent’’ model.
Here we briefly describe the time-dependent growth of an
epidemic based on the observable model, the compartments of
which are drawn in Figure 1A. Let JA(t,t) and JS(t,s) be the
numbers of asymptomatic and symptomatic cases at calendar time
t, infection-age t since infection and disease-age s since illness
onset. The growth of cases is described by:
L
Lt
z
L
Lt
 
JA(t,t)~{(g(t)zcA(t))JA(t,t),
L
Lt
z
L
Ls
 
JS(t,s)~{cS(s)JS(t,s),
ð1Þ
where g(t) is the rate at which asymptomatic cases develop
symptoms, and cA(t) and cS(s) are the rates at which asymptomatic
and symptomatic cases are fully recovered. We consider an initial
growth phase of an epidemic at which the depletion of susceptible
individuals S0 is negligible. Let l(t) be the force of infection, or the
rate at which susceptible individuals are infected. Two boundary
conditions, i.e., the new infection and new illness onset, are written
as
JA(t,0)~l(t)S0,
JS(t,0)~
ð?
0
g(t)JA(t,t)dt,
ð2Þ
Figure 1. Compartments of observable and unobservable
models. A. The compartment of an observable model. The model
describes the transitions depending on illness onset and recovery from
clinical symptoms. Once infected, all infected individuals experience
asymptomatic period, JA, some of which fully recover from infection
without symptoms, and the remaining develop symptoms, JS. B. The
compartment of an unobservable model. The model describes the
transitions depending on acquirement or disappearance of infectious-
ness. Upon infection, infected individuals experience the latent period
(i.e. Exposed compartment (E)) after which each acquires infectiousness
and is classified as either symptomatic (IS) or asymptomatic (IA) one. C.
The compartment of the special case of the observable model. The
model describes the transitions based on symptoms, but partially
accounts for infectiousness too. To let it be similar to model B, we
decomposed asymptomatic individuals, JA of the observable model
(panel A) into pre-symptomatic individuals, HS and fully asymptomatic
individuals with or without infectivity. U represents recovered
individuals.
doi:10.1371/journal.pone.0062062.g001
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where l(t) is, by adopting a mass action principle, parameterized
as:
l(t)~
ð?
0
bA(t)JA(t,t)dtz
ð?
0
bS(s)JS(t,s)ds, ð3Þ
where bA(t) and bS(s) are the infection-age and disease-age
dependent rates of secondary transmission, respectively. It should
be noted that the recovered individuals in Figure 1A are assumed
as no longer infectious. An advantage of this modeling approach is
that a reasonable computation of epidemiological measurements
(e.g. the reproduction number, the generation time and the serial
interval) can be achieved, adhering to observed available
information [8]. Moreover, transitions from the asymptomatic
state to the symptomatic or recovered state are in line with the
actual clinical course of infection, i.e., only a part of asymptomatic
individuals develop symptoms and the rest of infected individuals
recover from infection without symptoms.
The basic reproduction number of this model is computed as
follows ([8]):
R0~R1zaR2, ð4Þ
where R1, R2 and a are the average number of secondary cases
generated by a single asymptomatic case (only during the
asymptomatic period), the average number of secondary cases
generated by a single symptomatic case throughout the course of
the symptomatic period, and the conditional probability of
developing symptom given infection, respectively. The probability
of symptomatic illness, a is multiplied to R2 only, because all
infected individuals experience asymptomatic class while only the
fraction a of infected individuals result in symptomatic infection.
The model (1) is a stage-structured model in which the
reproduction number is calculated from the integral kernel of
the specific class of host in its renewal equation [11]. R1, R2 and a
are defined as
R1~S0
ð?
0
bA(t) exp {
ðt
0
(g(a)zcA(a))da
0
@
1
Adt,
R2~S0
ð?
0
bS(s) exp {
ðs
0
cS(a)da
0
@
1
Ads,
a~
ð?
0
g(x) exp {
ðx
0
(g(s)zcA(s))ds
0
@
1
Adx,
ð5Þ
which we will use in later discussion.
The other type of a model, i.e., the unobservable model, can be
said to be the infection-age structured SEIR model that further
classifies infectious individuals into symptomatic and asymptom-
atic cases [10] (Figure 1B). Let E(t,t), IA(t,t,s) and IS(t,t,s) be the
numbers of pre-infectious individuals, asymptomatic infectious
individuals and symptomatic infectious individuals, respectively, at
calendar time t, infection-age t and disease-age s. The dynamics is
described by
L
Lt
z
L
Lt
 
E(t,t)~{e(t)E(t,t),
L
Lt
z
L
Lt
 
IS(t,t)~ke(t)E(t,t){kS(t)IS(t,t),
L
Lt
z
L
Lt
 
IA(t,t)~(1{k)e(t)E(t,t){kA(t)IA(t,t),
ð6Þ
where e(t), kA(t) and kS(t) represent the rate of acquiring
infectiousness, and the recovery rates among asymptomatic and
symptomatic infectious individuals, respectively. k is the weight
(0#k#1) of the rate at which exposed individuals acquire
infectiousness that determines the probability of developing
symptom. A boundary condition for new infections is
E(t,0)~l(t)S0, ð7Þ
where the force of infection is
l(t)~
ð?
0
b(y) mIA(t,y)zIS(t,y)ð Þdy, ð8Þ
where b(t) represents the rate of secondary transmission at
infection-age t, and m represents the relative infectiousness of
asymptomatic cases as compared to symptomatic cases. The basic
reproduction number, R0, for this unobservable model is given by
R0~kR3z(1{k)R4, ð9Þ
where R3 and R4 are the average numbers of secondary cases
generated by a single asymptomatic case and a single symptomatic
case throughout the course of infectiousness, respectively. In
equation (9), k and (12k) are multiplied to R3 and R4, respectively,
because the probabilities of an infected individual to experience
symptomatic and asymptomatic infections are given by k and
(12k), respectively. Again, the reproduction numbers, R3 and R4,
are calculated from the integral kernel of the renewal process, i.e.,
we define
R3~S0
ð?
0
b(t)
ðt
0
e(x) exp {
ðx
0
e(y)dy{
ðt
x
kS(y)dy
0
@
1
Adxdt,
R4~mS0
ð?
0
b(t)
ðt
0
e(x) exp {
ðx
0
e(y)dy{
ðt
x
kA(y)dy
0
@
1
Adxdt:
ð10Þ
Using these two models under a homogeneously mixing
assumption, we investigate the importance of appropriately
capturing the observable natural course of infection in epidemi-
ological models.
Analytical and numerical analyses
To explicitly account for the observable clinical course of
infection, underlying assumptions of using a parameter k in the
Observable and Unobservable Modeling Approaches
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unobservable model as the probability of symptomatic infection
remain unclear (Figure 1B and system (6); because the transition
from E to I state does not have anything to do with illness onset).
Moreover, it is fruitful to identify different model assumptions
between two models and their practical relevance to infectious
disease control. Thus, here we take two different approaches to
identify the structural differences and different assumptions
between two models. First, we impose additional assumptions to
the observable model, thereby permitting it to resemble the SEIR-
like unobservable model. A simplistic analytical computation is
performed to mathematically determine the difference between
the two models. Second, we numerically compute the basic
reproduction numbers based on the two models. It is clear, even
intuitively, that the presence of pre-symptomatic transmission is a
major difference between the observable model and the unob-
servable SEIR type model. Thus, we examine the sensitivity of the
basic reproduction number to the proportion of pre-symptomatic
secondary transmissions among the total of asymptomatic
transmissions.
Subsequently, we investigate the differential impact of vaccina-
tion on the reproduction number (or, on the epidemic threshold) of
the two models. In a published study, the next-generation matrix
was employed to incorporate various different biological actions of
vaccination into the transmission dynamics under vaccination
[12]. However, the derivation of the next-generation matrix in the
published study remained heuristic, and moreover, the computa-
tion rested only on the unobservable SEIR-like model. Thus, here
we derive the next-generation matrix based on the linearized
system of both (1) and (6), measuring the impact of differential
model formulation on the reproduction number. When analyti-
cally computing the matrix, various different effects of vaccination
are considered, including not only the reductions in susceptibility
and infectiousness but also the reduction in the risk of symptomatic
illness [13].
Parameter values
For numerical illustration, we examine the plausible parameter
space for four different viral infectious diseases. Table 1 shows the
parameter values that are adopted to numerically calculate the
threshold quantities and other associated variables of observable
and unobservable models [8–10,12,14–24]. Smallpox is consid-
ered for the exposition of the similarity between two different
models, because it involves very few asymptomatic transmissions
[14,25,26]. HIV/AIDS is the opposite example of smallpox with
respect to the proportion of asymptomatic transmissions among
the total of secondary transmissions. Namely, the secondary
transmission mostly occurs before the onset of AIDS [8]. Influenza
and varicella are considered as examples that lie between smallpox
and HIV/AIDS. In particular, influenza is considered, because (i)
the unobservable model with asymptomatic and symptomatic
infectious individuals was initially employed with an application to
influenza [10] and (ii) a variety of vaccine effects have been
quantified based on challenge and community-based studies [12],
which offers a suitable condition to explore the impact of model
formulation on the transmission dynamics in the presence of
vaccination. It should be noted that successful vaccine of HIV has
yet to be offered [27] and the corresponding vaccine effect
parameters were only hypothetically assumed.
Results
Using observable model to mimic unobservable model
To analytically describe the difference between two modeling
approaches, we consider the unobservable model as a special case
of the abovementioned observable model. Figure 1C shows the
compartments of a variant of the observable model that are
intended to mimic the SEIR structure. To do this, we divide the
asymptomatic infected individuals JA(t,t) in Figure 1A into three
sub-populations, i.e., (i) pre-symptomatic individuals who are
supposed to develop symptom after spending the incubation
period, HS(t,t), (ii) asymptomatic non-infectious individuals who
will not become symptomatic throughout the course of infection,
HA(t,t), and (iii) asymptomatic infectious individuals, I(t,t). The
fate of experiencing symptomatic infection is determined upon
infection with a probability a, similarly to that taking place when
acquiring infectiousness in the SEIR model (Figure 1B). In the
following, those who remain asymptomatic throughout the
course of infection (i.e. HA+I) is referred to as ‘‘fully’’
asymptomatic, while those who eventually develop symptoms,
HS is referred to as ‘‘pre-symptomatic’’ for clarity. Recovered
individuals at calendar time t is denoted by U(t). The transition
rates from HS to JS, HA to I, JS to U, and I to U are g(t)/a, r(t),
cS(s), and fA(t), respectively, where t and s again represent the
infection-age and the disease-age, respectively. For consistency
between the observable and unobservable models, the transition
from Hs to Js is artificially scaled by a, because Js in the
observable model welcomes only the fraction a of infected
individuals to symptomatic class, which occurs not only during
the transition from Hs to Js but also when infected individuals
enter to Hs. The time-dependent growth of infected individuals is
described by
L
Lt
z
L
Lt
 
HS(t,t)~{
g(t)
a
HS(t,t),
L
Lt
z
L
Lt
 
HA(t,t)~{r(t)HA(t,t),
L
Lt
z
L
Ls
 
JS(t,s)~{cS(s)JS(t,s),
L
Lt
z
L
Lt
 
I(t,t)~r(t)HA(t,t){fA(t)I(t,t),
ð11Þ
with the following boundary conditions:
HS(t,0)~al(t)S0,
HA(t,0)~(1{a)l(t)S0,
JS(t,0)~
1
a
ðt
0
g(t)HS(t,t)dt,
ð12Þ
where the force of infection, l(t), is parameterized as
l(t)~m
ð?
0
bS(t)I(t,t)dtz
ð?
0
bH (t)HS(t,t)dtz
ð?
0
bS(s)JS(t,s)ds,
ð13Þ
where m is the relative infectiousness among those who remain
asymptomatic, bH and bS are the rates of transmission caused by
Observable and Unobservable Modeling Approaches
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pre-symptomatic and symptomatic individuals, respectively. It
should be noted that m is multiplied to only the first integral
term, because m is defined as the infectiousness of ‘‘fully’’
asymptomatic individuals relative to that among those who
experience symptomatic state in the observable model
(Figure 1B), as was defined elsewhere [10]. This scaling was
required to let the model in Figure 1A mimic the model in
Figure 1B. It is evident from Figure 1C that for the
unobservable model (Figure 1B) to agree with the observable
one (Figure 1C), the incubation period and the latent period
must be identical. Moreover, the recovery from an infectious
state should also be identical to the recovery from symptomatic
illness. Two models become consistent from each other if the
following conditions are met:
(a) a= k (i.e. assumed probabilities of symptomatic infection in
two models are identical),
(b) e(t) = g(t)/a=r(t) (i.e. the incubation period is identical to
the latent period; or equivalently, bH(t) = 0 for any t),
and (c) kS(t) = cS(s) and kA(t) = fA(s) (i.e., the recovery rates of
both models are an identical constant).
Writing in the way we computed the observable model in (4),
the basic reproduction number is computed as
R0~R
0
1zaR
0
2, ð14Þ
where
R
0
1~mS0
ð?
0
bS(t)
ðt
0
r(x) exp {
ðx
0
r(y)dy{
ðt
x
fA(y)dy
0
@
1
Adxdt
zS0
ð?
0
bH (t) exp {
ðt
0
g(x)
a
dx
0
@
1
Adt,
R
0
2~
S0
a
ð?
0
bS(s)
ðs
0
g(y) exp {
ðy
0
g(x)
a
dx{
ðs
y
cS(z{y)dz
0
B@
1
CAdyds:
ð15Þ
In summary, two models are rather different and can be
consistent only in the case that the model could be written by
ordinary differential equations and only when the incubation
period can be equated to the latent period.
Comparison of the basic reproduction number
We continue to compare the special case of the observable
model (Figure 1C) with the unobservable SEIR type model
(Figure 1B). As was implicated from abovementioned conditions
(a)–(c) to ensure consistency between the two models, it should be
noted that there is no concept of pre-symptomatic transmission in
Table 1. Parameter values for observable and unobservable models of directly transmitted infectious diseases.
Description Notation Parameter values References/Assumptions
Smallpox Influenza HIV Varicella
The average number of secondary
cases produced by an asymptomatic
case
R1 0.69 0.60 3.67 3.24 [14] & calculated
The average number of secondary
cases produced by a symptomatic
infection
R2 6.18 1.20 0.00 3.24 [14] & calculated
The average number of secondary
cases produced by a fully
asymptomatic case
Ra 1.37 0.96 6.12 6.47 [14] & calculated
Probability of developing symptoms
in the unobservable model
a (or k) 1.00 0.75 0.80 1.00 [10] & assumed
Basic reproduction number of the
observable model
R0 6.87 1.50 3.67 6.47 [14,15,16,17,18]
Proportion of asymptomatic
transmissions among all secondary
transmissions
h 0.10 0.40 1.00 0.50 [8,9,21,22]
Proportion of pre-symptomatic
transmissions among all
asymptomatic infection
g 1.00 0.60 0.67 1.00 [23] & calculated
Vaccine efficacy of reducing
infectiousness
VEI 0.80 0.15 0.60 0.80 [12,17,19,20,21,22,24] & assumed
Vaccine efficacy of reducing
susceptibility
VES 0.95 0.41 0.40 0.50 [12,17,19,20,21,22,24] & assumed
Vaccine efficacy of preventing
progression to symptomatic illness
VEP 0.87 0.67 0.60 0.50
{ [12,17,19,20,21,22,24] & assumed
{assumed.
doi:10.1371/journal.pone.0062062.t001
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the unobservable model. On the contrary, the special case
(Figure 1C) can still account for pre-symptomatic transmission as
long as we assume that bH(t).0. Let g represent the proportion of
pre-symptomatic transmissions among the total of asymptomatic
transmissions, then the basic reproduction number of the special
case model (14) is rewritten as follows:
R0~gR
0
1z(1{g)R
0
1zaR
0
2: ð16Þ
Let Ra and Rpre be the average numbers of secondary cases
generated by a single (fully) asymptomatic and pre-symptomatic
case, respectively. Using the weighted average of the reproduction
numbers with the proportion of symptomatic infections (e.g. as
practiced in (9)), R0 of the model that is intended to bridge the
observable model with the unobservable one (Figure 1C) can also
be expressed as
R0~(1{a)Raza(RprezR
0
2): ð17Þ
The average number of secondary cases generated by a single
fully asymptomatic case should be identical between (16) and (17),
i.e.,
(1{g)R
0
1~(1{a)Ra: ð18Þ
Similarly, the average number of secondary cases generated by
a single pre-symptomatic case should also be identical between the
two models as follows:
gR
0
1~aRpre: ð19Þ
Figure 2 examines the impact of g on the resulting estimate of
the basic reproduction number, varying only g (and the
corresponding a) in the model and using fixed values for all other
parameters in equations (16) and (17) (see Table 1). Note that g=0
is the special case in which the observable model (Figure 1C) is
fully consistent with the unobservable model. As g increases, R0 for
smallpox and influenza are elevated. However, R0 for HIV and
varicella are lowered as a function of g. Assuming that Rpre is
proportional to Ra, the differential sensitivity is understood by
considering the weighted average in (16) and (17). That is, we have
g~
aRpre
aRprez(1{a)Ra
, ð20Þ
or a= gRa/{(12g)Rpre+gRa}, indicating that the larger g, the larger
a has to be. Consequently, if the number of fully asymptomatic
transmissions is smaller than other transmissions (in the case of
influenza and smallpox), R0 is an increasing function of g.
However, when there are substantial pre-symptomatic transmis-
sions (e.g. HIV/AIDS), the relationship between R0 and g is
reversed.
Model building and vaccination
In the following, a comparison of the reproduction numbers
under vaccination is made between the observable model
(Figure 1A) and the unobservable model (Figure 1B). Because a
randomly mixing population is divided into vaccinated and
unvaccinated ones, we introduce the next-generation matrix. Let
p, 12qS, 12qI, and 12qD be the vaccination coverage, vaccine
efficacy in reducing susceptibility, infectiousness, and efficacy of
preventing symptomatic illness, respectively. As heuristically
derived elsewhere [12,13], the next-generation matrix that
describes secondary transmission between and among vaccinated
and unvaccinated cases is employed. Let y(t) be the so-called
reproduction kernel of the renewal process of the observable
model that describes the class-age dependent rate of secondary
transmission per single infected individual [28], i.e.,
y(t)~S0
(1{p) bA(t)L1(t)zbS(t)L2(t)L3(t)ð Þ
qSp bA(t)L1(t)zbS(t)L2(t)L3(t)ð Þ
 
qI (1{p) bA(t)L1(t)zqDbS(t)L2(t)L3(t)ð Þ
qSqIp bA(t)L1(t)zqDbS(t)L2(t)L3(t)ð Þ
!
,
ð21Þ
where the first row represents the exposure to unvaccinated
susceptible individuals. It should be noted that qD appears inside
parenthesis in the second column (i.e. secondary transmissions
caused by vaccinated cases). The survival rates L1(t), L2(t) and
L3(t) in (21) are written as
L1(t)~ exp {
ðt
0
(g(a)zcA(a))da
0
@
1
A,
L2(t)~ exp {
ðt
0
cS(a)da
0
@
1
A,
L3(t)~g(t) exp {
ðt
0
(g(a)zcA(a))da
0
@
1
A:
ð22Þ
The next-generation matrix of the observable model under
vaccination is given by the integral of y(t), i.e.,
K1~
ð?
0
y(t)dt
~
(1{p) R1zaR2ð Þ qI (1{p) R1zaqDR2ð Þ
qSp R1zaR2ð Þ qSqIp R1zaqDR2ð Þ
 !
:
ð23Þ
Let F(s) and L(s) be matrices that describe the class-age
dependent rate of the appearance of new infections and the
proportion of those who remain infectious, respectively, i.e.,
F (s)~S0
(1{p) kb(s)z(1{k)mb(s)½ 
qSp kb(s)z(1{k)mb(s)½ 
 
qI (1{p) kqDb(s)z(1{kqD)mb(s)½ 
qSqIp kqDb(s)z(1{kqD)mb(s)½ 
)
,
ð24Þ
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L(s)~
Ðs
0
e(x) exp {
Ðx
0
e(y)dy{
Ðs
x
kS(y)dy
 !
dx
0
0
BB@
0
Ðs
0
e(x) exp {
Ðx
0
e(y)dy{
Ðs
x
kA(y)dy
 !
dx
1
CA:
ð25Þ
The next-generation matrix of the unobservable model is
obtained from ([28]):
K2~
ð?
0
y(s)ds~
ð?
0
F(s)L(s)ds
~R3
(1{p) kzw(1{k)½  qI (1{p) kqDzw(1{kqD)½ 
qSp kzw(1{k)½  qSqIp kqDzw(1{kqD)½ 
 !
,
ð26Þ
where w is the ratio of R4 to R3 and is identical to m if kA= kB.
Note that qD only changes the weight of R3 (or R4) inside the
bracket of all elements. The effective reproduction number is the
dominant eigenvalue of these matrices, i.e.,
Rv,obs~(1{p) R1zaR2ð ÞzqSqIp R1zaqDR2ð Þ,
Rv,non~(1{p)R3 kzw(1{k)½ zqSqIpR3 kqDzw(1{kqD)½ ,
ð27Þ
where Rv,obs and Rv,non correspond to the reproduction numbers of
the observable and unobservable models, respectively. It should be
noted that only Rv,obs is consistent with the data generating process
of qD, while this is not the case for Rv,non, because qD in the
equation of Rv,non is assumed to have had an impact on the
transition rate from pre-infectious to infectious period (in addition
to the impact on the probability of symptom development alone;
Figure 1B).
To understand the extent of the different impact of qD on the
reproduction number between two models, Figure 3 compares the
values of Rv,obs and Rv,non for selected four diseases as a function of
vaccine-induced reduction in symptomatic illness, qD. By varying
qD, different patterns of variation in the reproduction number are
seen. For the examined three diseases, i.e., smallpox, influenza and
Figure 2. The basic reproduction number and the pre-symptomatic transmission. The impact of varying the proportion of pre-
symptomatic transmissions among all asymptomatic transmissions (the horizontal axis; denoted by g in the main text) on the basic reproduction
number, R0. Only the value of g (and the corresponding a) in the model is varied. All other parameters are fixed (see Tableoˆ 1). Shaded area represents
the plausible parameter region of the proportion of pre-symptomatic transmissions among the total asymptomatic transmissions, g, for a specific
disease.
doi:10.1371/journal.pone.0062062.g002
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varicella, Rv,non was greater than Rv,obs. The relationship was
reversed for HIV, and in particular, Rv,obs of HIV was
independent of qD due to the assumed absence of secondary
transmission following the onset of AIDS. Although the difference
is subtle for smallpox and varicella, the critical level of influenza is
clearly different between two models for influenza. Moreover, it
should be noted that the critical coverage is an inverse function of
the reproduction number, and a slightly greater reproduction
number based on the unobservable model could incorrectly
indicate us to vaccinate as many as additional 5–10% of the
population as compared to the coverage calculated from the
observable model. The difference in the critical coverage was most
apparent for HIV/AIDS.
Discussion
The present study analyzed and compared observable and
unobservable modeling approaches. Two major tasks have been
completed. First, by rewriting the observable model as if it were an
SEIR-type unobservable model, we aimed to clarify underlying
assumptions of the unobservable model that involves asymptom-
atic transmission. For the two models to be identical, we have
Figure 3. The effective reproduction number under vaccination practice. Effective reproduction numbers for the observable model and the
unobservable model are compared as a function of vaccine-induced reduction in symptomatic illness. To permit comparison, in the absence of
vaccination practice, the epidemic threshold values of the two models were assumed as identical. Vaccination coverage is fixed at 50%. The solid line
shows the reproduction number of the unobservable model under vaccination. The dashed line shows the reproduction number of the observable
model under vaccination. Except the vaccine-induced reduction in symptomatic illness, all parameters were fixed (see Tableoˆ 1). For the
unobservable model, relative infectiousness of asymptomatic individuals (compared to symptomatic individuals), m (or w), was arbitrarily fixed at 0.5
for three diseases other than varicella to which we assigned 0.7 (these particular values were arbitrarily chosen to visually demonstrate the difference
between two models).
doi:10.1371/journal.pone.0062062.g003
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demonstrated that it is essential that the incubation period has to
be identical to the latent period and also that no pre-symptomatic
transmission occurs in both models. Only the observable model
can directly incorporate vaccine-induced reduction in symptom-
atic illness (in the manner that the corresponding vaccine effect
data is generated), and the probability of symptomatic infection in
the unobservable model was shown to be multiplied to the
transition rate from pre-infectious to infectious state without
phenomenological justification. Second, we numerically solved
both models and examined the sensitivity of R0 to the frequency of
pre-symptomatic transmission. We identified that the ignorance of
pre-symptomatic transmission in the unobservable model can lead
to an overestimate of R0. Moreover, we have shown that the
critical coverage of vaccination can be different between two
models, because the vaccine efficacy of preventing symptomatic
illness would influence the threshold in different mathematical
manners.
The present study emphasizes that an appropriate model
formulation would be essential to answer the corresponding
scientific or public health question. As we have shown, an explicit
formulation would also help clarify underlying assumptions that
tend to be hidden in common model structures. Considering a
practical example of vaccination that influences the symptom
onset, we have shown that the modeling approach to tackle this
issue requires a model building approach that can explicitly
account for the natural course of infection including asymptomatic
and symptomatic states. Since the use of SEIR structure with two
or more types of I-classes with different levels of symptom or
clinical severity has also partially accounted for this matter of
differential severity of symptom, and because the unobservable
modeling approach to this issue has been proposed relatively early
[10], the similar model structure has become widely adopted in a
variety of settings in studying influenza and other directly
transmitted infectious diseases [29–35]. However, we have shown
that the unobservable model has to inherently adopt an
assumption that there is no pre-symptomatic transmission, and
in this model, vaccine-induced reduction in symptomatic illness
has to influence the transition from pre-infectious to infectious
state [12]. To explicitly and appropriately incorporate the vaccine
effect in reducing the risk of a symptomatic disease into the model,
it is fruitful to employ a model that directly accounts for disease
progression.
Although our discussion might read as if we regard the
observable model as always better than the unobservable one,
this preference cannot always be true. In fact, the observable
model is not perfect, largely missing the information of infectious-
ness in the model structure. However, if we handle the model
fitting to the incidence of illness onset, the observable model must
be most useful, because the renewal equation of only symptomatic
cases can be computed and directly fitted to the data [8]. If our
study objective was not to quantitatively measure model param-
eters based on observable empirical data (e.g. model fitting to real
data), the unobservable model may be more useful in many other
objectives (e.g. in considering the loss of infectiousness during the
isolation period). Rather than emphasizing that we should regard
the observable model as a default, we would like to emphasize that
writing this particular issue from multiple angles would be useful
for mathematical modeling studies; the present study was a single
study that focused on symptom-based modeling approach in
contrast to a classical one. Moreover, it should be noted that
‘‘theoretically’’ the best model in this context would be the one
that accounts for both observable and unobservable information
within a single model. Such a model can easily address the
dependence structure between clinical illness and infectiousness
[36], and indeed, the potential dependence and difference between
the incubation period and the latent period are known as critical
factors in determining the effectiveness of public health interven-
tions including contact tracing and case isolation [9,37–39]. As
demonstrated by animal experiments for foot and mouth disease
[38], an appropriate combination of well-designed experiments (or
observations) and statistical inference could shed light on the
scientific approach to (i) considering both illness and infectiousness
and (ii) identifying ideal modeling strategy in the future [40].
Four limitations should be noted and described briefly. First, we
conducted only univariate sensitivity analysis, ignoring any
possible dependence between the frequency of pre-symptomatic
transmissions among the total asymptomatic transmissions and
other epidemiological variables. Ignoring such dependence struc-
ture could sometimes lead to overestimating the effectiveness of
public health interventions [41]. Second, we focused on the basic
reproduction number, and did not extend epidemiological insights
into other important quantities (e.g. growth rate of infections)
[42,43]. Third, to keep the matter as simple as possible, our
arguments rested on homogeneously mixing assumptions. Fourth,
whereas our model rested on fixed compartment structures
(Figure 1), the structure of model ultimately depends on specific
diseases and study objectives [44].
Considering that we were successful in gaining useful epidemi-
ological insights into future quantitative modeling by formulating
the vaccination issue using an observable model, it is suggested
that more studies based on observable epidemiological variables
are conducted. Future studies can also tackle the issue of
abovementioned dependence between clinical illness and infec-
tiousness based on an explicit model with both pieces of
information as variables and analyzing individual datasets with
multiple dimensions.
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